Biogen
BIIB
1,012 hedge funds and large institutions have $59.3B invested in Biogen in 2016 Q3 according to their latest regulatory filings, with 121 funds opening new positions, 338 increasing their positions, 399 reducing their positions, and 67 closing their positions.
81% more first-time investments, than exits
New positions opened: 121 | Existing positions closed: 67
33% more funds holding in top 10
Funds holding in top 10: 43 → 57 (+14)
27% more capital invested
Capital invested by funds: $46.5B → $59.3B (+$12.8B)
5% more funds holding
Funds holding: 965 → 1,012 (+47)
6% less call options, than puts
Call options by funds: $1.49B | Put options by funds: $1.59B
15% less repeat investments, than reductions
Existing positions increased: 338 | Existing positions reduced: 399
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$368M |
| 2 |
Jennison Associates
New York
|
+$180M |
| 3 |
JP Morgan Chase
New York
|
+$154M |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$118M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$116M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$510M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$303M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$303M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$163M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$114M |
BIIB Hedge Fund Activity: Q3 2016 in Review
1,012 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2016, worth a combined $59.3B — up 27% from $46.5B a quarter earlier.
Buyers outnumbered sellers: 121 funds opened new BIIB positions and 67 closed out — a net gain of 54 holders — while 338 added to existing stakes and 399 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $368M. The largest seller was Fidelity Investments, cutting an estimated $510M.
- 1,012 institutional investors held Biogen (BIIB) as of Q3 2016, up from 965 in Q2 2016.
- Funds reported $59.3B of Biogen stock for Q3 2016, up 27% quarter-over-quarter.
- 121 funds opened new Biogen positions in Q3 2016 and 67 closed out, a net change of +54 holders.
- The largest Biogen buyer in Q3 2016 was T. Rowe Price Associates, an estimated $368M added.
- The largest Biogen seller in Q3 2016 was Fidelity Investments, an estimated $510M sold.
Based on aggregated 13F filings for Q3 2016.